Royalty Pharma PLC (NASDAQ:RPRX) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants George Grofik - SVP & Head, IR & Communications Pablo Legorreta - Founder, Chairman & CEO Christopher Hite - Vice Chairman & EVP Terrance Coyne - EVP & CFO Marshall Urist - EVP & Head, Research & Investments Conference Call Participants Christopher Schott - JPMorgan Chase & Co. Stephen Scala - TD Cowen Andrew Baum - Citigroup Michael DiFiore - Evercore ISI Chris Shibutani - Goldman Sachs Group ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (State or other jurisdiction of incorporation or organization) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ ...

Royalty Pharma plc (NASDAQ:RPRX) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Pablo Legorreta - Chief Executive Officer Marshall Urist - Executive Vice President, Head of Research and Investment Terrance Coyne - Executive Vice President, Chief Financial Officer Chris Hite - Executive Vice President, Vice Chairman George Grofik - Head of Investor Relations and Communications Conference Call Participants Chris Shibutani - Goldman Sachs Hardik Parekh - JP Morgan Geoff Meacha ...

ROYALTY PHARMA Q2 2023 Financial Results 2 Also, the discussions during this conference call will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). Additional information regarding non-GAAP financial measures can be found on slide 24 and in the Company's earnings release furnished with its Current Report on Form 8-K dated August 8, 2023, which are available on the Company's website. Any non-GAAP financial measures presented a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 ...

Q1 2023 Financial Results Forward Looking Statements & Non-GAAP Financial Information 3 | --- | --- | --- | |-------------------|----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------| | Portfolio Update | Marshall Urist | EVP, Head of Research & Investments | | Financial Results | Terrance Coyne | EVP, Chief Financial Officer | | Conclusion | Pablo Legorreta | Founder & Chief Executiv ...

Royalty Pharma plc (NASDAQ:RPRX) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head-Investor Relations and Communications Pablo Legorreta – Founder and Chief Executive Officer Marshall Urist – Executive Vice President, Head-Research and Investments Terry Coyne – Executive Vice President and Chief Financial Officer Chris Hite – Executive Vice President and Vice Chairman Conference Call Participants Chris Shibutani – Goldman Sachs Chris Sch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 ...

Royalty Pharma plc (NASDAQ:RPRX) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants George Grofik - Senior Vice President, Head of Investor Relations & Communications Pablo Legorreta - Founder & Chief Executive Officer Christopher Hite - Executive Vice President & Vice Chairman Marshall Urist - Executive Vice President & Head of Research and Investments Terry Coyne - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sach ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (State ...